Formulation and Process Optimization of Cinnarizine Fast-Release Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Formulation and Process Optimization of Cinnarizine Fast-Release Tablets
The authors prepared granules containing cinnarizine using polyethylene glycol 6000 as a melting binder and lactose monohydrate as hydrophilic filler. The effects of binder concentration and size were studied.


Pharmaceutical Technology
Volume 33, Issue 8, pp. 53-59


Figure 9: Granule size distribution after various granulation times. (FIGURE IS COURTESY OF THE AUTHORS)
An SEM study (see Figure 8) showed that at 10 min of granulation, the mechanism of granule growth was nucleation, and at 20 min, nucleation was followed by agglomeration, whereby initial nuclei were formed and coalescence of particles took place.


Figure 10: Granule size distribution at various fluidized air velocities. (FIGURE IS COURTESY OF THE AUTHORS)
Effect of fluidizing air velocity. The data presented in Table I show the operating conditions used to investigate the influence of fluidizing air velocity (batches M11–M14). The variation in median size correlated with increased fluidizing air velocity. In all cases, the granule size was lower at a higher velocity. At the lowest fluidizing air velocity (350 m3/h), reduction in solids motion resulted in local overwetting, thus causing the defluidization of the bed. As the fluidized air velocity increased from 450 m3/h to 650 m3/h, mean granule size decreased, which may be attributed to the increase in the number of collisions at a faster velocity (see Figure 10).


Figure 11: Scanning electron microscopy (SEM) images of granules produced at (a) 60 °C and (b) 68 °C. (FIGURE IS COURTESY OF THE AUTHORS)
Effect of bed temperature. Table I lists the experimental conditions used to study the effect of bed temperature (batch M15–M18). At 60 °C, materials are completely fluidized and granules were produce with superior characteristics. When granulation was attempted at higher temperatures (64 and 68 °C), the bed defluidized and many lumps formed. The main cause for this occurrence is that these operating bed temperatures fall within the melting range of the binders, thereby inhibiting binder solidification to form granules. The authors' investigation into the influence of bed temperature using PEG 6000 clearly showed that the mean diameter of granules increased with increased bed temperature. The former observation can be explained by the hypothesis of Vander Scheur on the basis of the difference in binder solidification and heat transfer rate at increased bed temperature. For example, a higher bed temperature will induce a slower binder solidification rate, and the binder will remain molten for a longer period. This means the binder will have more time to promote more particle aggregation before it solidifies, thus leading to a faster growth rate with increased bed temperature (15).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here